Navigation Links
Osteotech Completes Tissue Supply Agreement With LifeNet Health
Date:10/16/2007

EATONTOWN, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE) announced today that it has entered into a tissue supply agreement with LifeNet Health, Inc. Pursuant to the agreement, LifeNet Health will provide Osteotech with tissue which will be utilized by Osteotech for its core DBM, Biocomposite and Collagen Technologies. The agreement was effective September 1, 2007, has an initial five-year term which can be terminated earlier by either party on six months notice, and automatically renews for successive two-year terms unless terminated by either party six months prior to renewal. Osteotech currently has an agreement with LifeNet Health and its distribution partner, Depuy Spine, for the processing and distribution of a private label DBM.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, commented, "We are extremely pleased to have expanded our relationship with LifeNet Health. We respect and support LifeNet Health's commitment to saving lives and restoring health. LifeNet Health has an excellent reputation and their commitment to tissue donation is outstanding."

Mr. Owusu-Akyaw continued, "Our tissue supply arrangements with LifeNet Health and Community Tissue Services provide a strong foundation for our tissue needs in future years. We will continue to pursue our strategic initiatives to establish additional relationships with other tissue recovery organizations and tissue banks."

LifeNet Health, founded in 1982, is a full service biomedical tissue banking system and a leading non-profit organ and tissue donation agency whose mission is saving lives and restoring health. LifeNet Health provides recovery and processing services for musculoskeletal and cardiovascular tissues, distributing more than 225,000 biomedical implants every year to restore health to patients around the world.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions to surgeons and patients for the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com .

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of October 17, 2007 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. iGATE Completes Phase I Testing Of Meningitis Vaccine
2. Delhi Hospital Completes 100 Liver Transplants
3. Roche Completes Acquisition of BioVeris
4. New drug to treat Heart Attack and damaged tissue
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. Leeches help in tissue transfer
7. Bone marrow stem cells may help repair cardiac tissues
8. Free Tissue Transfer Effective in Treating Massive Skin Cancers
9. Tissue Transfer for Skin Cancer
10. Tissue Transfer For Treatment Of Massive Skin Cancers
11. Loss Of Brain Tissue Linked To Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Alert Sentry Group LLC., a leader in the Personal Emergency Response ... and the iSAFE Plus. These iSAFE products are the most affordable and most advanced ... iSAFE Plus offer direct GPS Location and two-way calling with the push of a ...
(Date:3/28/2017)... Greifensee, Switzerland (PRWEB) , ... March 28, 2017 ... ... testing for laboratory instruments are critical to ensuring high-quality results and maintaining GMP ... and Qualification of Laboratory Instruments in accordance with GMP requirements " these requirements ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... measurement of corrosive ions found in power plant water and steam. , Chlorides ... as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... will be offered by the American Association of Integrative Medicine and available for ... healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... CAMBRIDGE, England , March 28, 2017 ... in collaborative research with Cambridge ... Milner Therapeutics Consortium   The Milner Therapeutics Institute ... Therapeutics Consortium. Elysium Health has committed significant investment for collaborative ... over the next four years. This is the first major ...
Breaking Medicine Technology: